Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Joaquin Duato | M | 61 | 35 years | |
| Kathryn Wengel | F | 58 | 36 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Russell C. Deyo | M | 74 | 27 years | |
| Alex Gorsky | M | 63 | 35 years | |
| James Sapirstein | M | 63 |
Tobira Therapeutics, Inc. /Old/
 Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | 5 years |
| Laurent Fischer | M | 60 |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | 7 years |
| Michael H. Ullmann | M | 66 | 33 years | |
| John Johnson | M | 66 | 19 years | |
| John Tattory | M | 58 | 12 years | |
| Andrew Hindman | M | 51 |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | 3 years |
| Thomas Miller | M | 52 | 11 years | |
| Helen Jenkins | F | 60 |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | - |
| Mary Templeton | F | 78 | - | |
| James Cullen | M | 81 | 20 years | |
| Russell Clayton | M | 63 | - | |
| Jack L. Bowman | M | 91 | 7 years | |
| Robert E. Campbell | M | 90 | 36 years | |
| Martin Madden | M | 64 | 31 years | |
| Tom Manion | M | 70 | 8 years | |
| Ralph S. Larsen | M | 85 | 19 years | |
| Ray Ogle | M | - | - | |
| Duncan Fatkin | M | - | 11 years | |
| Robert O’Holla | M | 72 | 18 years | |
| David John Bailey | M | 75 | - | |
| Gerald Ostrov | M | 73 | 15 years | |
| Angelo Scopelianos | M | 69 | 24 years | |
| Miguel Patricio | M | 57 | 6 years | |
| Don Casey | M | 64 | - | |
| Kevin Mosher | M | - | 4 years | |
| Robin T. Barney | F | 62 | - | |
| Michelle Harrison | M | - | 3 years | |
| Noreen Dishart | F | - | 7 years | |
| Chris Calabretta | M | - | 26 years | |
| Michael Sneed | M | 65 | 39 years | |
| Martine Kraus | M | - |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | - |
| William McComb | M | 61 | 14 years | |
| Nevin Grinnell | M | - | 3 years | |
| Kenneth J. Tack | M | - | 6 years | |
| Jack Butler | M | - | 7 years | |
| Gerald Bruce | M | 68 | 15 years | |
| Manuel Aguero | M | 62 | 6 years | |
| Patrick W. McNallen | M | - | 2 years | |
| Tomas Jan Heyman | M | 68 | 23 years | |
| Sennen Pamich | M | - | 6 years | |
| Davide Gallotti | M | 65 | 5 years | |
| John Knowlton | M | - | - | |
| Adam T. Rumage | M | - | 9 years | |
| Chao C. Chen | M | 70 | 25 years | |
| Marianne de Backer | M | 55 | 28 years | |
| Michael G. Dapper | M | - | - | |
| Ralph Christopher Cavalli | M | 65 | 7 years | |
| Christopher J. Stergion | M | 58 | 15 years | |
| Ken Berlin | M | 59 | 13 years | |
| Eric Lefebvre | M | 60 |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | - |
| Pierre B. Pirard | M | 56 | 15 years | |
| Mark Erlander | M | 64 | 6 years | |
| Steven J. Gavel | M | - | - | |
| Geert Cauwenbergh | M | 70 | 8 years | |
| Maximillian D. Fiore | M | 69 | 4 years | |
| Ivan Delevic | M | 59 | 4 years | |
| Andrew Dahlkemper | M | 57 | 4 years | |
| Syed M. J. Kazmi | M | 67 | 7 years | |
| Charles F. Katzer | M | 74 | 4 years | |
| Peter Wehrly | M | 65 | 17 years | |
| Gérard Vaillant | M | 82 | 17 years | |
| Mark G. Osterman | M | - | 2 years | |
| Paul J. Guagliardo | M | - | 3 years | |
| Karen Prange | F | 60 | 17 years | |
| Jean-Luc Butel | M | 67 | 6 years | |
| Peter D. Bewley | M | 77 | 17 years | |
| Nadav Friedmann | M | 81 | 11 years | |
| James L. Natale | M | 77 | 15 years | |
| Deni M. Zodda | M | 70 | 6 years | |
| Bill Doyle | M | 61 | 5 years | |
| Christopher Schaber | M | 57 | 8 years | |
| Michael C. Chen | M | 74 | 9 years | |
| George A. Ziets | M | 77 | 7 years | |
| Arnold G. Langbo | M | 86 | 19 years | |
| Seth Fischer | M | 68 | 29 years | |
| Ron Hunt | M | 59 | 7 years | |
| David Anderson | M | 71 | 6 years | |
| Alan Kerzner | M | - | 4 years | |
| Kenneth G. Hayes | M | - | 17 years | |
| Marc Wipperman | M | - | 19 years | |
| Tony Vernon | M | 69 | 23 years | |
| Arlene Morris | F | 72 | 16 years | |
| David M. Clapper | M | 72 | 16 years | |
| Donald Duffy | M | 87 | 22 years | |
| Marvin L. Miller | M | 87 | 3 years | |
| Gerard N. Burrow | M | - | 12 years | |
| Per A. Peterson | M | 79 | 13 years | |
| Alan Dunton | M | 70 | 7 years | |
| Bruno A. Melzi | M | 76 | 10 years | |
| Thomas M. Tully | M | 78 | 8 years | |
| Dan Eckert | M | 59 | 2 years | |
| Kathryn Cole | F | 59 | 15 years | |
| William W. Crouse | M | 80 | - | |
| Mark Adams | M | 62 | 3 years | |
| Maxine Frank Singer | M | - | 12 years | |
| Pericles Stamatiadis | M | - | 28 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Kathleen A. McGowan
- Personal Network
